Sildenafil Use in a Symptomatic Neonate with Severe Ebstein's Anomaly of the Tricuspid Valve

ABSTRACT

Ebstein's anomaly (EA) is associated with poor outcome in symptomatic neonates. Management typically includes prostaglandins or surgical creation of a Blalock-Taussig shunt. Right ventricular afterload reduction may help by improving the forward flow across the pulmonary valve. We report the successful use of oral sildenafil, a pulmonary vasodilator, in a neonate with severe EA.

KEYWORDS

Ebstein's anomaly - sildenafil - cyanosis - neonate

REFERENCES

• 1 Celermajer D S, Bull C, Till J A et al.. Ebstein's anomaly: presentation and outcome from fetus to adult.  J Am Coll Cardiol. 1994;  23 170-176
• 2 Yetman A T, Freedom R M, McCrindle B W. Outcome in cyanotic neonates with Ebstein's anomaly.  Am J Cardiol. 1998;  81 749-754
• 3 Pavlova M, Fouron J C, Drblik S P et al.. Factors affecting the prognosis of Ebstein's anomaly during fetal life.  Am Heart J. 1998;  135 1081-1085
• 4 Celermajer D S, Cullen S, Sullivan I D et al.. Outcome in neonates with Ebstein's anomaly.  J Am Coll Cardiol. 1992;  19 1041-1046
• 5 Bruckheimer E, Bulbul Z, Pinter E et al.. Inhaled nitric oxide therapy in a critically ill neonate with Ebstein's anomaly.  Pediatr Cardiol. 1998;  19 477-479
• 6 Schulze-Neick I, Hartenstein P, Li J et al.. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.  Circulation. 2003;  108(Suppl 1) II167-II173
• 7 Atz A M, Lefler A K, Fairbrother D L et al.. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises.  J Thorac Cardiovasc Surg. 2002;  124 628-629
• 8 Gentles T L, Calder A L, Clarkson P M et al.. Predictors of long-term survival with Ebstein's anomaly of the tricuspid valve.  Am J Cardiol. 1992;  69 377-381
• 9 Ivy D, Loehr J, Schaffer M. Usefulness of prolonged prostaglandin infusion in neonates with Ebstein's anomaly.  Am J Cardiol. 1993;  72 1327-1329
• 10 Corbin J D, Beasley A, Blount M A et al.. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.  Biochem Biophys Res Commun. 2005;  334 930-938
• 11 Humpl T, Reyes J T, Holtby H et al.. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.  Circulation. 2005;  111 3274-3280
• 12 Pham P, Hoyer A, Shaughnessy R et al.. A novel approach incorporating sildenafil in the management of symptomatic neonates with Ebstein's anomaly.  Pediatr Cardiol. 2006;  27 614-617